Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

2(22%)

Results Posted

67%(4 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_4

11%

Ph early_phase_1

22%

Ph phase_1

33%

Ph phase_2

22%

Ph phase_3

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Early Phase 1First-in-human

2(22.2%)

Phase 1Safety & dosage

3(33.3%)

Phase 2Efficacy & side effects

2(22.2%)

Phase 3Large-scale testing

1(11.1%)

Phase 4Post-market surveillance

1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(6)

Terminated(1)

Detailed Status

Completed6

Recruiting1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (22.2%)

Phase 13 (33.3%)

Phase 22 (22.2%)

Phase 31 (11.1%)

Phase 41 (11.1%)

Trials by Status

recruiting111%

terminated111%

completed667%

active_not_recruiting111%

Recent Activity

2 active trials

Showing 5 of 9

active_not_recruitingearly_phase_1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women

NCT05597098

recruitingphase_3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918

terminatedphase_1

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

NCT03426995

completedphase_1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

NCT03306589

completedphase_2

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

NCT03017846

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT05597098Early Phase 1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women

Active Not Recruiting

NCT07457918Phase 3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Recruiting

NCT03426995Phase 1

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

Terminated

NCT03306589Phase 1

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed

NCT03017846Phase 2

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

Completed

NCT03625960Phase 4

Cantharone for the Treatment of Perenial Warts

Completed

NCT01026064Phase 1

Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides

Completed

NCT01582321Early Phase 1

Investigation of the Influence of Gender on Cardiovascular Function

Completed

NCT02665260Phase 2

Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9